Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Internal Medicine

Pediatrics

Surgery

Public Health, Environmental And Occupational Health

Show all topics

DOI

10.1016/s1470-2045(14)70243-8